Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ICLR by emailGet an email when ICLR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ICLR, unsubscribe in one click. Privacy
📣 What ICLR Says Is Next
fourth quarter · “On May 26, 2026, the Company issued a press release announcing that it will release financial results for the fourth quarter and full year 2025 results after the market closes on Wednesday, May 27, 2026 and also receipt of the Notice.”
Company press release, May 26, 2026 · SEC filing
fourth quarter · “Document Exhibit 99.1 ICON plc update on issuance of full-year 2026 guidance On January 7, 2025, ICON plc announced that, further to prior updates regarding the timing for issuance of full-year 2026 guidance, ICON confirms that it intends to issue full-year 2026 guidance alongside the release of our fourth quarter and full-year 2025 results.”
Company press release, Jan 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ICLR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ICLR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.